Pulmonary hypertension often has a lethal outcome in systemic sclerosis and the treatment is challenging. Epoprostenol is a potent pulmonary vasodilator and its efficacy has been demonstrated when delivered by the intravenous and aerosolized routes. We report the haemodynamic and functional benefits of epoprostenol administered by inhalation to a spontaneously breathing patient with partially reversible pulmonary hypertension due to systemic sclerosis. Aerosolized epoprostenol, equivalent to the maximum tolerated intravenous dose (31.2 micrograms), produced a 58% fall in pulmonary vascular resistance, increased the cardiac output by 42% and improved functional performance by one MET (3.5 ml kg-1 min-1 of oxygen uptake) without any significant side-effects. Selective distribution of epoprostenol by the inhaled route may offer a new strategy for treatment of pulmonary hypertension.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0954-6111(99)90294-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
cSTAR analysis identifies endothelial cell cycle as a key regulator of flow-dependent artery remodeling.
Sci Adv
January 2025
Yale Cardiovascular Research Center, Yale School of Medicine, New Haven, CT 06511, USA.
Fluid shear stress (FSS) from blood flow sensed by vascular endothelial cells (ECs) determines vessel behavior, but regulatory mechanisms are only partially understood. We used cell state transition assessment and regulation (cSTAR), a powerful computational method, to elucidate EC transcriptomic states under low shear stress (LSS), physiological shear stress (PSS), high shear stress (HSS), and oscillatory shear stress (OSS) that induce vessel inward remodeling, stabilization, outward remodeling, or disease susceptibility, respectively. Combined with a publicly available database on EC transcriptomic responses to drug treatments, this approach inferred a regulatory network controlling EC states and made several notable predictions.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
Centre for Brain Research, Indian Institute of Science, Bangalore, Karnataka, India.
Background: Pulmonary Function Tests (PFTs) are the non-invasive tests to measure the lung function. Relationship between pulmonary function and cognition is an emerging area of research, understanding this is crucial for prevention and management of dementia. Hence this study aims to investigate the association between pulmonary function and cognition.
View Article and Find Full Text PDFIloprost: Old and New Indications.
Cardiol Rev
January 2025
From the Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY.
Iloprost is a synthetic long-acting prostacyclin-analog drug used to treat various vascular diseases. The Federal Drug Administration approved the drug in 2004 for pulmonary arterial hypertension, and it has since been shown to be helpful in other vascular conditions such as scleroderma and Raynaud phenomenon. The Federal Drug Administration has now approved the use of iloprost for severe frostbite.
View Article and Find Full Text PDFMitochondrial calcium uniporter complex: An emerging therapeutic target for cardiovascular diseases (Review).
Int J Mol Med
March 2025
Department of Cardiology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421000, P.R. China.
Cardiovascular disease (CVD) is currently a major factor affecting human physical and mental health. In recent years, the relationship between intracellular Ca and CVD has been extensively studied. Ca movement across the mitochondrial inner membrane plays a vital role as an intracellular messenger, regulating energy metabolism and calcium homeostasis.
View Article and Find Full Text PDFAdrenomedullin in pulmonary hypertension.
Dan Med J
November 2024
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine.
Adrenomedullin (AM) exerts strong pulmonary vasodilatory effects. These effects are mediated in part by nitric oxide. Plasma AM levels are increased in patients with pulmonary hypertension and correlate with disease severity and poor outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!